Results 81 to 90 of about 1,849,474 (227)

Treatment ofClostridioides (Clostridium) difficileinfection

open access: yesAnnals of Medicine, 2019
Clostridioides (formerly: Clostridium) difficile infection (CDI) is a major cause of diarrhoea for inpatients as well as outpatients. Usually, CDI is healthcare-associated but the number of community-acquired infections is increasing. CDI is generally associated with changes in the normal intestinal microbiota caused by administration of antibiotics ...
Oksi Jarmo   +2 more
openaire   +4 more sources

Pediatric Clostridiodes difficile infection with toxic megacolon successfully treated with fecal microbiota transplantation

open access: yesJPGN Reports, EarlyView.
Abstract The rising incidence of pediatric Clostridioides difficile infection (CDI), particularly in medically complex patients, calls for novel, individualized treatments. While fecal microbiota transplantation (FMT) is well‐described for recurrent CDI, this report describes the first pediatric case of fulminant CDI with toxic megacolon successfully ...
Dana McCarney   +3 more
wiley   +1 more source

Case report of two patients with recurrent watery stools following prophylactic ileostomy reversal after rectal cancer surgery

open access: yes结直肠肛门外科
The causes of diarrhea after enterostomy reversal may be related to surgical treatment, and its severity varies. Clinical interventions are often based on the patient’s symptomatic presentation.
Shen Shuai, Gao Hui
doaj   +1 more source

Clostridioides Difficile Infection

open access: yesDiseases of the Colon & Rectum, 2020
Linda, Ferrari, Alessandro, Fichera
openaire   +5 more sources

Vedolizumab use for severe chronic enterocolitis in a child with Hoyeraal–Hreidarsson syndrome: A case report

open access: yesJPGN Reports, EarlyView.
Abstract We report a patient with Hoyeraal–Hreidarsson syndrome (HHS), a telomere biology disorder, who developed severe chronic enterocolitis with inflammatory bowel disease‐like features. Vedolizumab led to improvement in stool frequency, reduced fecal calprotectin, and clinical remission without infectious complications.
Yasutaka Chiba   +6 more
wiley   +1 more source

Clostridioides difficile (formerly known as Clostridium difficile) [PDF]

open access: yes
Clostridioides difficile (also known as C. diff ) is a bacterium that causes diarrhea and colitis (an inflammation of the colon). C. diff infection can be life-threatening.CS316107-APublication date from document properties.Cdiff-Factsheet-P ...

core  

Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objectives Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs. Methods ACS‐NSQIP (2019–2023)
Amir Ebadinejad   +4 more
wiley   +1 more source

A decade of Clostridioides difficile infection: a constant challenge to maintain the status quo

open access: yes, 2023
Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated (HA) diarrhoea. We retrospectively investigated data from a comprehensive, multidisciplinary C.
Caoimhe Finn (14783729)   +11 more
core  

Association of enteral nutrition reduction or discontinuation with diarrhea volume and caloric delivery in critically ill adults with diarrhea: A retrospective cohort study

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background When critically ill patients receiving enteral nutrition (EN) develop diarrhea, clinicians often reduce or discontinue EN, although evidence supporting this practice is limited. We examined the association between EN management after diarrhea and diarrhea volume in critical care patients.
Ryohei Yamamoto   +4 more
wiley   +1 more source

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

open access: yes, 2023
Sandhya Nagarakanti, Robert Orenstein Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ, USACorrespondence: Sandhya Nagarakanti, Mayo Clinic Arizona, Division of Infectious Diseases, 577 East Mayo Boulevard, Phoenix, AZ, 85054, USA, Tel ...
Nagarakanti S, Orenstein R
core  

Home - About - Disclaimer - Privacy